Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Interferon-alpha in cutaneous T-cell lymphoma]

¹Abteilung für Spezielle Dermatologie und Umweltdermatosen, Dermatologischen Universitätsklinik Wien.

Wiener Medizinische Wochenschrift (1946)

|January 1, 1993

Summary

Low-dose interferon-alpha (IFN-alpha) combined with retinoids effectively treats cutaneous T-cell lymphoma (CTCL), inducing long-term remissions with minimal side effects. Preliminary data also suggest improved remission rates with IFN-alpha combined with other therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Same author

Corrigendum: Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Same author

European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Same author

European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Same author

Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.

The British journal of dermatology·2020

Same author

Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

The British journal of dermatology·2020

Area of Science:

Oncology
Dermatology
Immunology

Background:

Cutaneous T-cell lymphoma (CTCL) treatment varies based on disease stage and location.
Interferon-alpha (IFN-alpha) therapy shows 40-50% response rates in CTCL, dependent on disease stage.

Purpose of the Study:

To evaluate the efficacy of low-dose IFN-alpha combined with retinoids for CTCL treatment.
To explore the potential of other IFN-alpha combinations in improving CTCL remission rates.

Main Methods:

Combination therapy using low-dose interferon-alpha and retinoids.
Analysis of preliminary data for IFN-alpha combined with standard and experimental therapies (e.g., Pentostatin).

Main Results:

The combination of low-dose IFN-alpha and retinoids achieved long-term remissions in CTCL patients.

Related Experiment Videos

This combination demonstrated a low incidence of side effects.

Preliminary findings suggest improved remission rates when IFN-alpha is combined with other therapies.

Conclusions:

Low-dose IFN-alpha and retinoid combination therapy is an effective treatment for CTCL with a favorable safety profile.
Further investigation into IFN-alpha combinations may enhance CTCL treatment outcomes.